Bruker Corporation (US) and Revvity, Inc. (US) are Leading Players in the Preclinical Imaging Market
The preclinical imaging market is projected to reach USD 5101 million by 2029 from USD 3997 million in 2024, at a CAGR of 5.0% from 2024 to 2029. In vivo preclinical imaging involves the visualization of animal models required during life science research studies. This is particularly important to academic researchers and those involved in drug development activities, prior to human trials. During a drug development process, preclinical studies provide vital information about the drug candidate (such as its therapeutic effects, pharmacodynamics profile, and side effects & toxicities). This forms basis for regulatory approval to initiate clinical trial on humans.
The market growth is mainly driven by factors such as rising demand for new drug development, innovations in preclinical imaging, and growing number of public-private initiatives and funding to support preclinical researches. However, strict regulations inhibit the growth of the market.
To know about the assumptions considered for the study download the pdf brochure
The global preclinical imaging market is highly fragmented and competitive, with a significant number of global and regional market players. The major players operating in this market are Kub Technologies (US), Medikor (US), Trifoil Imaging (US), IVIM Technology Corp. (South Korea), Cubresa, Inc. (Canada), Berthold Technologies GMBH & CO.KG (Germany), Miltenyi Biotech GmbH (Germany), Sofie (US), Fujifilm Visual Sonics (Canada), MILABS B.V. (Netherlands), Aspect Imaging Limited (US), Li-Cor Biosciences (US), ICONEUS (Paris), Advanced Molecular Vision (UK), Viewworks (Korea), AI4R (France), Bruker Corporation (US), Revvity, Inc. (US), MR Solutions (UK), and Mediso Ltd. (UK).
Bruker Corporation (US)
Bruker Corporation (U.S.) stands out in the preclinical imaging market. The company has a broad portfolio of preclinical imaging systems, comprising optical imaging, micro-MRI, micro-CT, preclinical magnetic particle imaging, and trimodality (PET/SPECT/CT) imaging systems. In order to strengthen its current position and gain a larger share in the global preclinical imaging market, the company primarily focuses on expanding its preclinical imaging product portfolio by launching technologically advanced products in the market. In February 2023, the company launched SKYSCAN 2214 CMOS EDITION, a multiscale X-ray microscope based on nano-CT (computed tomography) for industrial and academic research. The SKYSCAN 2214 platform incorporates the latest scientific CMOS (sCMOS) detector technology and brings cutting-edge X-ray imaging at highest resolution to the next level. The company also focuses on acquisitions as its key strategy to ensure its growth in the global preclinical imaging market. In February 2024, Bruker acquired Spectral Instruments Imaging. This acquisition fills a gap in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging (PCI) division, broadening its range of preclinical solutions for disease research.
Revvity, Inc. (US)
Revvity specializes in providing comprehensive health science solutions, technologies, expertise, and services spanning the entire spectrum from discovery to development, and diagnosis to treatment. Their areas of expertise include translational multi-omics technologies, biomarker identification, imaging, predictive analytics, screening and diagnosis tools, detection systems, informatics solutions, and more. Its comprehensive portfolio of technologies gives a competitive advantage in the preclinical imaging market. During fiscal year 2023, the company delivered differentiated performance despite market headwinds, demonstrating the strength of the product portfolio, continued innovation, and investments in their people.
Related Reports:
Preclinical Imaging Market by Product Type (Optical Imaging, PET, SPECT, Optical Imaging Reagents, Contrast Agents, Nuclear Imaging Reagents), Application (Oncology, Neurology), End User (Pharmaceutical, Imaging Centers) - Global Forecast to 2029
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
